Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders

Authors

  • Albert Saiz MD,

    1. Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic, Serveis, Spain
    Search for more papers by this author
  • Francesc Graus MD,

    Corresponding author
    1. Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic, Serveis, Spain
    • Neurology Service, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain
    Search for more papers by this author
  • Josep Dalmau MD,

    1. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY
    Search for more papers by this author
  • Alex Pifarré PhD,

    1. Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic, Serveis, Spain
    Search for more papers by this author
  • Concepció Marín MD,

    1. Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic, Serveis, Spain
    2. Banc De Teixits Neurologics, Serveis, Spain; Científico-Tènics, University of Barcelona, Barcelona, Spain
    Search for more papers by this author
  • Eduardo Tolosa MD

    1. Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic, Serveis, Spain
    2. Banc De Teixits Neurologics, Serveis, Spain; Científico-Tènics, University of Barcelona, Barcelona, Spain
    Search for more papers by this author

Abstract

The detection of 14-3-3 protein in cerebrospinal fluid by immunoblotting is useful for the diagnosis of Creutzfeldt-Jakob disease (CJD). We found 14-3-3 protein in 10 of 80 (12.5%) patients with paraneoplastic neurological disorders (PNDs), whose presenting symptoms may mimic those of CJD. In 47 of 48 CJD patients, the 14-3-3 protein was detected as a single band, and it was detected as a double band in 1 patient. The double-band pattern was observed in 9 of the 10 14-3-3 protein–positive patients with PNDs. The 14-3-3 protein assay may be positive in PND patients, but the immunoblotting pattern distinguishes most PND samples from those of CJD.

Ancillary